Ahmad, FaizSarder, AmitGour, RajeshKarna, Shibendra Kumar LalArora, PriyaKartha, P. RavindranathanPokharel, Yuba Raj2020-12-072020-12-072020-05-11https://www.excli.de/index.php/excli/article/view/22901611-2156http://hdl.handle.net/2003/3985210.17877/DE290R-21743Cancer is a generic term for a large group of diseases characterized by the growth of abnormal cells, which is the second leading cause of death globally. To treat cancer, currently, a number of anticancer drugs belonging to various classes chemically are available. The discovery of artemisinin and its derivatives such as artesunate, arteether, and artemether became a milestone in the cure for malaria. Here, we report the anti-cancer property of anhydrodihydroartemisinin (ADHA) - a semisynthetic derivative of artemisinin against prostate cancer cell line PC-3. ADHA was found to be inhibiting growth of PC-3 cells. ADHA was also found to be inhibiting migration of PC-3 cells. At molecular level, ADHA was found to be inhibiting the expression of c-Jun, p-c-Jun, p-Akt and NF-κB and activated caspase 3 and 7. The results show that ADHA like few other artemisinin derivatives hold potential to be used as an anti-cancer agent against prostate cancer cells.enIfADo - Leibniz Research Centre for Working Environment and Human Factors, DortmundEXCLI Journal;Vol. 19. 2020, p. 613-619AnhydrodihydroartemisininPC-3ApoptosisCaspase 3Caspase 7c-JunAktNF-κB610article (journal)